U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

Merck CEO Robert Davis spoke about the new state-of-the-art biologics center slated to be based in Wilmington, Delaware that ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Merck is investing $1 billion to build a U.S. plant in Delaware, in a show of its commitment to domestic manufacturing.

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

According to Merck, the total investment is now expected to be over $1 billion, with 500 full-time jobs and 4,000 construction jobs expected on the job site. The laboratory component of the new site ...

Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...

Take our quiz to find your perfect hiking trail near Philly. Plus, the Pennsylvania impact of President Trump's first 100 ...

Created by branding agency Koto, Amazon's new global brand identity is shaped by its revitalised logo – the first new design ...